| Literature DB >> 34295742 |
Florian A Stroie1, Matthew D Houlihan2, Tobias S Kohler2.
Abstract
Squamous cell carcinoma of the penis is a rare malignancy among men in North America and Europe with an incidence of <1 per 100,00 men. Of all genitourinary cancers, penile carcinoma has the potential to jeopardize sexual function the most. The treatment modalities of penile carcinoma span the gamut from organ-sparing treatments such as topical therapy, laser therapy, radiotherapy, glansectomy, wide-local excision and partial or total penectomy. There is a relative paucity of data in the medical literature describing the impact of penile cancer treatment on sexual function. The majority of available studies use retrospective data from small samples utilizing heterogeneous study tools such as patient interviews and non-validated questionnaires. The most commonly used validated instrument to evaluate sexual outcomes is the International Index of Erectile Function Questionnaire (IIEF), but is limited in that it does not assess patients who perform self-stimulation or achieve sexual stimulation by any means other than penetrative intercourse. Though advances in clinical research continue; large, well-designed comparative studies using validated instruments are elusive. The sexual outcomes after penile cancer are reviewed from the available published data to better assist the patient and the treating physician with medical decision making. With a detailed assessment of sexual outcomes, the physician is better equipped in providing patient centered care to achieve outcomes meaningful for each patient. 2021 Translational Andrology and Urology. All rights reserved.Entities:
Keywords: Penile cancer; organ-sparing surgery; penectomy; sexual function
Year: 2021 PMID: 34295742 PMCID: PMC8261429 DOI: 10.21037/tau-20-1228
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Summary of main available data in the literature evaluating sexual function outcomes in the penile cancer survivor
| Treatment type | Number of patients | Evaluation of sexual function | Validated instrument data | Subjective assessment of outcomes by authors | Year | Bibliography reference |
|---|---|---|---|---|---|---|
| Laser ablation | 224 | Follow-up encounter | N/A | Good | 2008 | 12 |
| 46 | Face-to-face, semi-structured interview, IIEF, non-validated survey, | IIEF: moderate ED in 1 patient; mild ED in 3 patients | Good | 2004 | 13 | |
| Total glans resurfacing | 7 | IIEF, non-validated survey | IIEF: No ED in 7 patients | Good | 2006 | 14 |
| 5 | Follow-up encounter | N/A | Good | 2007 | 37 | |
| 14 | IIEF | IIEF: 17.5 (mild ED, n=14) | Mild | 2020 | 39 | |
| Brachytherapy | 23 | IIEF, IMGI | IIEF: 20 (mild ED, n=23); IMGI: 21 (satisfied with genitalia image, n=23) | Mild | 2018 | 15 |
| 19 | IIEF, BASIC IDEA survey | IIEF: 21 (mild-moderate ED, n=17) | Moderate | 2014 | 16 | |
| 19 | IIEF, BASIC IDEA survey | IIEF: no ED in 7 patients; mild ED in 1 patient, mild-moderate ED in 1 patient, severe ED in 10 patients | Moderate | 2014 | 17 | |
| Circumcision/wide local excision | 22 | IIEF | N/A | Good | 2011 | 21 |
| 27 | IIEF | IIEF: 13.5 (mild-moderate ED, n=27) | Mild | 2019 | 31 | |
| Wide local excision | 12 | IIEF, SEP | IIEF: 16.5 (mild-moderate ED, n=12); SEP2: no change, SEP3: diminished by 12.5% | Good | 2015 | 22 |
| 7 | IIEF, EDITS | IIEF: 22.4 (mild ED, n=7); EDITS: 80/100 | Good | 2018 | 38 | |
| 54 | IIEF | IIEF: 14.3 (moderate ED, n=54) | Moderate | 2014 | 30 | |
| Glansectomy | 23 | IIEF, SEP | IIEF: 15.7 (mild-moderate ED, n=23); SEP2: diminished by 27.3%, SEP3: diminished by 39.2% | Moderate | 2015 | 22 |
| 6 | IIEF | IIEF: 7.3 (severe ED, n=6) | Poor | 2015 | 23 | |
| 15 | Follow-up encounter | N/A | Good | 2009 | 25 | |
| 11 | Follow-up encounter | N/A | Mild | 2011 | 26 | |
| 42 | IIEF | N/A | Good | 2013 | 27 | |
| 5 | Follow-up encounter | N/A | Mild | 2007 | 37 | |
| 6 | IIEF | IIEF: 18 (mild ED, n=6) | Mild | 2020 | 39 | |
| Partial penectomy | 8 | IIEF | IIEF: 16 (moderate ED, n=8) | Moderate | 2018 | 24 |
| 17 | IIEF | IIEF: 17.7 (mild-moderate ED, n=17) | Mild | 2020 | 29 | |
| 36 | IIEF | IIEF: 11.3 (moderate ED, n=36) | Moderate | 2014 | 30 | |
| 13 | IIEF | IIEF: 16.7 (mild ED, n=13) | Mild | 2019 | 31 | |
| 18 | IIEF | IIEF: 19.3 (mild-moderate ED, n=18) | Moderate | 2005 | 32 | |
| 6 | IIEF | IIEF: 6.5 (severe ED, n=6) | Poor | 2018 | 33 | |
| 43 | IIEF | IIEF: 17.8 (mild-moderate ED, n=43) | Moderate | 2016 | 34 | |
| 10 | SFQ | N/A | Moderate | 2018 | 35 | |
| 14 | SFQ | N/A | Mild | 1997 | 36 | |
| 25 | IIEF, QEQ, EDITS | IIEF: 21.2 (mild-moderate ED, n=25); QEQ: 77/100; EDITS: 74/100 | Mild | 2015 | 2 | |
| 7 | Follow-up encounter | N/A | Mild | 2007 | 37 | |
| 8 | IIEF, EDITS | IIEF: 20.3 (mild-moderate ED, n=8); EDITS: 79/100 | Mild | 2018 | 38 | |
| 12 | IIEF | IIEF: 19 (mild ED, n=12) | Mild | 2020 | 39 |
IIEF, International Index of Erectile Function; IMGI, Index of Male Genital Image; BASIC IDEA, Behavior, Affect, Sensation, Imagery, Cognition, Interpersonal, Drugs, Expectation, Attitude; SEP, Sexual Encounter Profile; EDITS, Erectile Dysfunction Inventory of Treatment Satisfaction; SFQ, Sexual Function Questionnaire; QEQ, Quality of Erection Questionnaire; N/A, not applicable or available.